For Research Use Only

FGFR4 Polyclonal antibody

Catalog Number:11098-1-AP

Featured Product 18 Publications



Basic Information	Catalog Number: 11098-1-AP	GenBank Accession Number: BC011847	Purification Method: Antigen affinity purification	
	Size:	GenelD (NCBI):	Recommended Dilutions:	
	150ul , Concentration: 600 ug/ml by	2264	WB 1:200-1:1000	
	Nanodrop;	UNIPROT ID:	IHC 1:50-1:500	
	Source:	P22455	IF/ICC 1:50-1:500	
	Rabbit	Full Name:		
	Isotype: IgG	fibroblast growth factor receptor 4		
	Immunogen Catalog Number: AG1573	Calculated MW: 88 kDa		
		Observed MW: 100-110 kDa		
Applications	Tested Applications:	Positive Controls: WB : HepG2 cells, mouse lung tissue		
	WB, IHC, IF/ICC, ELISA			
	Cited Applications: WB, IHC, IF	IHC : huma	IHC : human breast cancer tissue, IF/ICC : HepG2 cells,	
	Species Specificity: human, mouse, rat	IF/ICC : He		
	Cited Species: human, mouse			
	Note-IHC: suggested antigen r TE buffer pH 9.0; (*) Alternati retrieval may be performed w buffer pH 6.0	vely, antigen		
	Fibroblast growth factor receptor 4 (FGFR4) is a member of a highly conserved tyrosine kinase family, along with FGFR1-3. This family consists of an intracellular tyrosine kinase domain, a single transmembrane domain, and extracellular ligand binding domains (PMID:32492514). FGFR4 is the predominant FGFR isoform present in human hepatocytes. FGFR4 has been proposed to play a role in the observed induction of hepatocyte proliferation and carcinogenesis by FGF19; however, contradicting evidence proposing a protective role for FGFR4 in suppressing hepatoma progression has also been proposed(PMID:20018895). While the role of FGFR4 in cancer remains to be fully elucidated, several findings suggest that this receptor may be an important player in Hepatocellular carcinom (HCC) development and/or progression(PMID:10336501).			
Background Information	FGFR1-3. This family consists of an in extracellular ligand binding domain hepatocytes. FGFR4 has been propos carcinogenesis by FGF19; however, c hepatoma progression has also been fully elucidated, several findings sug	s (PMID:32492514). FGFR4 is the pre- ed to play a role in the observed indi ontradicting evidence proposing a p proposed(PMID:20018895). While th ggest that this receptor may be an im	a single transmembrane domain, and dominant FGFR isoform present in humar uction of hepatocyte proliferation and rotective role for FGFR4 in suppressing te role of FGFR4 in cancer remains to be	
	FGFR1-3. This family consists of an in extracellular ligand binding domain hepatocytes. FGFR4 has been propos carcinogenesis by FGF19; however, c hepatoma progression has also been fully elucidated, several findings sug (HCC) development and/or progressi	s (PMID:32492514). FGFR4 is the pre- ed to play a role in the observed indu ontradicting evidence proposing a p proposed(PMID:20018895). While th ggest that this receptor may be an im on(PMID:10336501).	a single transmembrane domain, and dominant FGFR isoform present in humar uction of hepatocyte proliferation and rotective role for FGFR4 in suppressing le role of FGFR4 in cancer remains to be portant player in Hepatocellular carcinor	
	FGFR1-3. This family consists of an in extracellular ligand binding domain hepatocytes. FGFR4 has been proposi- carcinogenesis by FGF 19; however, of hepatoma progression has also been fully elucidated, several findings sug (HCC) development and/or progression Author Pub	s (PMID:32492514). FGFR4 is the pre- ed to play a role in the observed indi ontradicting evidence proposing a p proposed(PMID:20018895). While th ggest that this receptor may be an im	a single transmembrane domain, and dominant FGFR isoform present in humar uction of hepatocyte proliferation and rotective role for FGFR4 in suppressing te role of FGFR4 in cancer remains to be	
Background Information	FGFR1-3. This family consists of an inextracellular ligand binding domain hepatocytes. FGFR4 has been proposicarcinogenesis by FGF19; however, or hepatoma progression has also been fully elucidated, several findings sug (HCC) development and/or progression Author Pub Limin Wang 363	s (PMID:32492514). FGFR4 is the pre- ed to play a role in the observed indi- ontradicting evidence proposing a p proposed(PMID:20018895). While th ggest that this receptor may be an im on(PMID:10336501).	a single transmembrane domain, and dominant FGFR isoform present in humar uction of hepatocyte proliferation and rotective role for FGFR4 in suppressing se role of FGFR4 in cancer remains to be portant player in Hepatocellular carcinor Application IF	
	FGFR1-3. This family consists of an in extracellular ligand binding domain hepatocytes. FGFR4 has been proposicarcinogenesis by FGF 19; however, of hepatoma progression has also been fully elucidated, several findings sug (HCC) development and/or progressionAuthorPub Limin WangYanan Chen316	s (PMID:32492514). FGFR4 is the pre- ed to play a role in the observed indi- ontradicting evidence proposing a p proposed(PMID:20018895). While th gest that this receptor may be an im- on(PMID:10336501). med ID Journal 505369 Tissue Eng Part A	a single transmembrane domain, and dominant FGFR isoform present in humar uction of hepatocyte proliferation and rotective role for FGFR4 in suppressing se role of FGFR4 in cancer remains to be portant player in Hepatocellular carcinon Application IF	
	FGFR1-3. This family consists of an in extracellular ligand binding domain hepatocytes. FGFR4 has been proposicarcinogenesis by FGF 19; however, of hepatoma progression has also been fully elucidated, several findings sug (HCC) development and/or progressionAuthorPub Limin WangYanan Chen316	s (PMID:32492514). FGFR4 is the prevented to play a role in the observed indi- ontradicting evidence proposing a p proposed(PMID:20018895). While the ggest that this receptor may be an im- on(PMID:10336501).	a single transmembrane domain, and dominant FGFR isoform present in humar Juction of hepatocyte proliferation and rotective role for FGFR4 in suppressing le role of FGFR4 in cancer remains to be portant player in Hepatocellular carcinol Application IF	

T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: proteintech@ptglab.com

in USA), or 1(312) 455-8498 (outside USA)

W: ptglab.com

Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data




HepG2 cells were subjected to SDS PAGE followed by western blot with 11098-1-AP (FGFR4 antibody) at dilution of 1:400 incubated at room temperature for 1.5 hours.



Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 11098-1-AP (FGFR4 antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 11098-1-AP (FGFR4 antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using 11098-1-AP (FGFR4 antibody) at dilution of 1:50 and Alexa Fluor 488conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).